Eli Lilly pays METiS TechBio up to $1.1B for lipid nanoparticle work
The AI-driven collaboration targets tissue-specific delivery vehicles; the companies did not disclose how much of the total is guaranteed.
TR
By Tom Reyes · Markets Editor
Oct 21 10:23 ETSource: BioPharma Dive
The wire
- 01Eli Lilly will work with Hong Kong-based METiS TechBio on AI-designed lipid nanoparticles for tissue-specific delivery, in a deal worth up to $1.1 billion. Separately, TriGemX Bio, formerly Kallyope, will go public via a TCGX SPAC with $246 million in cash.
- 02TriGemX began as a gut-brain axis company and has since sold off its obesity drug programs, leaving migraine candidate elismetrep in late-stage testing.
- 03Lilly and METiS did not break out upfront versus milestone payments, and the TriGemX cash comprises $86 million in SPAC reserves plus a $160 million private investment.
From the source
Read at biopharmadive.comArcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
